The Pitt Bacteremia Score, Charlson Comorbidity Index and Chronic Disease Score are useful tools for the prediction of mortality in patients with Candida bloodstream infection

Mycoses ◽  
2017 ◽  
Vol 60 (10) ◽  
pp. 676-685 ◽  
Author(s):  
María Paz Vaquero-Herrero ◽  
Silvio Ragozzino ◽  
Fabián Castaño-Romero ◽  
María Siller-Ruiz ◽  
Rebeca Sánchez González ◽  
...  
Keyword(s):  
Chronic Disease ◽  
Bloodstream Infection ◽  
Charlson Comorbidity Index ◽  
Disease Score ◽  
Chronic Disease Score ◽  
Prediction Of Mortality ◽  
Comorbidity Index ◽  
Candida Bloodstream Infection

scholarly journals A novel superior medication-based chronic disease score predicted all-cause mortality in independent geriatric cohorts

2019 ◽  
Vol 105 ◽  
pp. 112-124 ◽  
Author(s):  
Renate Quinzler ◽  
Michael H. Freitag ◽  
Birgitt Wiese ◽  
Martin Beyer ◽  
Hermann Brenner ◽  
...  
Keyword(s):  
Chronic Disease ◽  
Disease Score ◽  
Chronic Disease Score ◽  
All Cause Mortality

PREDICTION OF MORTALITY FOLLOWING RADICAL PROSTATECTOMY BY CHARLSON COMORBIDITY INDEX

2008 ◽  
Vol 179 (4S) ◽  
pp. 559-559
Author(s):  
Paul Dluzniewski ◽  
Ryan Orosco ◽  
Elizabeth A Platz ◽  
Alan W Partin ◽  
Misop Han
Keyword(s):  
Radical Prostatectomy ◽  
Charlson Comorbidity Index ◽  
Prediction Of Mortality ◽  
Comorbidity Index

The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients

2008 ◽  
Vol 61 (12) ◽  
pp. 1234-1240 ◽  
Author(s):  
Mary E. Charlson ◽  
Robert E. Charlson ◽  
Janey C. Peterson ◽  
Spyridon S. Marinopoulos ◽  
William M. Briggs ◽  
...  
Keyword(s):  
Primary Care ◽  
Chronic Disease ◽  
Charlson Comorbidity Index ◽  
Primary Care Patients ◽  
Comorbidity Index

scholarly journals Description of a systematic pharmaceutical care approach intended to increase the appropriateness of medication use by elderly patients

2014 ◽  
Vol 87 (2) ◽  
pp. 119-129
Author(s):  
Daniela Petruta Primejdie ◽  
Louise Mallet ◽  
Adina Popa ◽  
Marius Traian Bojita
Keyword(s):  
Health Care ◽  
Nursing Home ◽  
Chronic Disease ◽  
Pharmaceutical Care ◽  
Active Drug ◽  
Care Team ◽  
Disease Score ◽  
Drug Related Problems ◽  
Chronic Disease Score ◽  
Care Approach

Background & Aims. The pharmaceutical care practice represents a model of responsible pharmacist involvement in the pharmacotherapy optimization of various population groups, including the elderly, known to be at risk for drug-related problems. Romanian pharmacists could use validated pharmaceutical care experiences to confirm their role as health-care professionals.This descriptive research presents the application in two real and different environments of practice of a structured pharmaceutical care approach conceived as the basis for a medication review activity and aiming at the identification and resolution of the drug related problems in the elderly.Patients and methods. Two patients with similar degree of disease-burden complexity, receiving care in different health-care environments (The Geriatric Ward of the Royal Victoria Hospital from the McGill University Health Centre in Montréal, Québec, Canada, in November 2010, and an urban nursing-home facility in Cluj-Napoca, Romania, in March 2011), were chosen for the analysis. One clinical pharmacist suggested solutions for the management of each of the active drug-related problems identified, using the systematic pharmaceutical care approach and specific published geriatric pharmacotherapy recommendations. The number of the drug-related problems identified and the degree of the care-team acceptance of the pharmacists’ solutions were noted for each patient.Results. The pharmacist found 6 active drug-related problems for the hospitalized patient (72 year-old, Chronic Disease Score 9) and 7 potential ones for the nursing-home resident (79 year-old, Chronic Disease Score 8), involving misuse, underuse and overuse of medications. Each patient had 3 geriatric syndromes at baseline. The therapy changes suggested by the pharmacist were implemented for the hospitalized patient, through collaboration with the health-care team. For the nursing home resident, the pharmacist identified the need for additional 6 medications and safety and efficacy arguments to cease 7 initial therapies, simplifying the therapeutic daily schedule (from 24 daily doses to 15).Conclusion. The pharmacist’s potential contribution to the optimization of the Romanian elderly patients’ pharmacotherapy needs further exploration, as potential drug related problems reported as characteristic for this population were easily identified. The presented structured and validated model of pharmaceutical care approach could be used to this end. Its dissemination and use could be encouraged along with the enhancement of pharmacotherapy information and care team collaboration skills.

Development and Validation of the Modified Charlson Comorbidity Index in Incident Peritoneal Dialysis Patients: A National Population-Based Approach

2017 ◽  
Vol 37 (1) ◽  
pp. 94-102 ◽  
Author(s):  
Hyunjeong Cho ◽  
Myoung-Hee Kim ◽  
Hyo Jin Kim ◽  
Jae Yoon Park ◽  
Dong-Ryeol Ryu ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Charlson Comorbidity Index ◽  
Clinical Decision Making ◽  
Proportional Hazards Model ◽  
Cox Regression ◽  
Relative Weight ◽  
Cox Proportional Hazards Model ◽  
Net Reclassification Improvement ◽  
Prediction Of Mortality ◽  
Comorbidity Index

Background The utility of applying the Charlson comorbidity index (CCI) to peritoneal dialysis (PD) patients is disputed because the relative weight of each comorbidity in PD patients may be different from those in other chronic diseases. We aimed to develop and validate a modified CCI in incident PD patients (mCCI-IPD) for better risk stratification and prediction of mortality. Methods The mCCI-IPD was developed using data from all Korean adult incident PD patients between 2005 and 2008 ( n = 7,606). Multivariate Cox regression was used to determine new weights for the individual comorbidities in the CCI. The prognostic performance of the mCCI-IPD was validated in an independent cohort ( n = 664) through c-statistics and continuous net reclassification improvement (cNRI). Results A total of 75.5% of the patients in the development cohort had 1 or more comorbidities. The Cox proportional hazards model provided reassigned severity weights for the 11 comorbidities that significantly predicted mortality. In the validation cohort, the CCI and mCCI-IPD scores were both correlated with survival and showed no differences in their c-statistics. However, multivariate analyses using cNRI revealed that the mCCI-IPD provided a 38.2% improvement in mortality risk assessment compared with the CCI (95% confidence interval [CI], 15.3 – 61.0; p < 0.001). These significant reclassification improvements were observed consistently in subjects with events (cNRIEvent, 28.2% [95% CI, 6.9 – 49.5; p = 0.009]) and without events (cNRINon-event, 10.0% [95% CI, 1.7 – 18.2; p = 0.019]). Conclusions Compared with the CCI, the mCCI-IPD showed better performance in mortality prediction for incident PD patients. Therefore, this tool may be used as a preferred index for statistical analysis and clinical decision-making.

Sign in / Sign up

Export Citation Format

Share Document